|
A phase II, randomized trial of standard of care with or without midostaurin to prevent relapse following allogeneic stem cell transplantation in patients with FLT3-ITD mutated acute myeloid leukemia. |
|
|
Consulting or Advisory Role - Athersys; Novartis |
Research Funding - Athersys |
Patents, Royalties, Other Intellectual Property - Athersys |
Travel, Accommodations, Expenses - Athersys; Janssen |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - Bristol-Myers Squibb (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Speakers' Bureau - Sanofi |